**Name of Journal: *World Journal of Biological Chemistry***

**ESPS Manuscript No: 31153**

**Manuscript Type: REVIEW**

**Retroviral integrase protein and intasome nucleoprotein complex structures**

Grawenhoff J *et al*. Structural analysis of retroviral integrase and intasomes

**Julia Grawenhoff, Alan N Engelman**

**Julia Grawenhoff,** **Alan N Engelman,** Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, United States

**Julia Grawenhoff,** **Alan N Engelman,** Department of Medicine, Harvard Medical School, Boston, MA 02115, United States

**Author contributions:** Grawenhoff Jand Engelman AN conceived the review and wrote the manuscript.

**Supported by** US National Institutes of Health grant, No. R01AI070042.

**Conflict-of-interest statement:** Authors declare no conflicts of interest for this article.

**Open-Access:** This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to: Alan N Engelman, PhD, Professor** of Medicine, Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, 450 Brookline Avenue, CLS-1010, Boston, MA 02215, United States. alan\_engelman@dfci.harvard.edu

**Telephone:** +1-617-6324361

**Fax:** +1-617-6324338

**Received:** November 1, 2016

**Peer-review started:** November 4, 2016

**First decision:** December 14, 2016

**Revised:** December 24, 2016

**Accepted:** January 11, 2017

**Article in press:**

**Published online:**

**Abstract**

Retroviral replication proceeds through the integration of a DNA copy of the viral RNA genome into the host cellular genome, a process that is mediated by the viral integrase (IN) protein. IN catalyzes two distinct chemical reactions: 3’-processing, whereby the viral DNA is recessed by a di- or trinucleotide at its 3’-ends, and strand transfer, in which the processed viral DNA ends are inserted into host chromosomal DNA. Although IN has been studied as a recombinant protein since the 1980s, detailed structural understanding of its catalytic functions awaited high resolution structures of functional IN-DNA complexes or intasomes, initially obtained in 2010 for the spumavirus prototype foamy virus (PFV). Since then, two additional retroviral intasome structures, from the α-retrovirus Rous sarcoma virus (RSV) and β-retrovirus mouse mammary tumor virus (MMTV), have emerged. Here, we briefly review the history of IN structural biology prior to the intasome era, and then compare the intasome structures of PFV, MMTV, and RSV in detail. Whereas the PFV intasome is characterized by a tetrameric assembly of IN around the viral DNA ends, the newer structures harbor octameric IN assemblies. Although the higher order architectures of MMTV and RSV intasomes differ from that of the PFV intasome, they possess remarkably similar intasomal core structures. Thus, retroviral integration machineries have adapted evolutionarily to utilize disparate IN elements to construct convergent intasome core structures for catalytic function.

**Key words:** Retrovirus; DNA integration; Integrase; Intasome; 3-dimensional structure; Prototype foamy virus; Mouse mammary tumor virus; Rous sarcoma virus; Human immunodeficiency virus/acquired immune deficiency syndrome

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** This review examines the history of retroviral integrase structural biology and covers the currently available high-resolution structures of retroviral intasomes in detail. We in particular focus on the similarities and differences among the intasome structures of prototype foamy virus, Rous sarcoma virus and β-retrovirus mouse mammary tumor virus.

Grawenhoff J, Engelman AN. Retroviral integrase protein and intasome nucleoprotein complex structures. *World J Biol Chem* 2017; In press

**INTRODUCTION**

Retroviral replication requires the incorporation of the viral genetic information into the host cellular genome, which occurs *via* two main steps: (1) the reverse transcription of single-stranded viral RNA into linear double-stranded DNA; and (2) the integration of this DNA into a host chromosome. These steps occur in the context of two subviral nucleoprotein complexes: the reverse transcription complex (reviewed in[1]) and the pre-integration complex (PIC)[2], each of which consists of a variety of cellular and viral proteins including reverse transcriptase (RT) and integrase (IN)[3-7]. In the cytoplasm, RT mediates the synthesis of a linear viral DNA (vDNA) molecule that harbors a copy of the viral long-terminal repeat (LTR) at each end[8-10]. In the confines of the PIC, vDNA is trafficked toward the nucleus, where its integration into host cell target DNA (tDNA) is promoted by IN. Here, we discuss the current knowledge of IN structural determinants and intasome function, highlighting both key similarities and differences among the retroviruses.

**REACTIONS CATALYZED BY IN**

Retroviral IN performs two biochemically and temporally distinct bimolecular nucleophilic substitution (SN2) reactions[11]: 3’-processing and strand transfer (Figure 1). During 3’-processing, a di- or trinucleotide is hydrolytically cleaved from each 3’ vDNA end[12-14], exposing reactive hydroxyl groups of invariant CA dinucleotides. These groups act as nucleophiles for subsequent strand transfer whereby the newly processed 3’ vDNA ends are covalently inserted into a major groove of tDNA in a staggered fashion. The product of the second reaction is an integration intermediate that is characterized by unjoined 5’ vDNA overhangs[15,16]. Following disassembly of the associated strand transfer complex (STC, Figure 1), a DNA polymerase, 5’ flap endonuclease, and DNA ligase are required to fill in the single-strand gap regions in tDNA, excise 5’ vDNA overhangs, and join the vDNA 5’ ends to host DNA strands, respectively (reviewed in[17]). During this process, short target site duplications are generated, which flank the integrated provirus. Depending on the genus of retrovirus, the size of these target site duplications ranges from 4-6 base pairs (bp). Whereas spumavirus PFV[18,19] and lentivirus human immunodeficiency virus 1 (HIV-1)[20,21] integration yield 4 bp and 5 bp target site duplications, respectively, MMTV[22] and RSV[23,24] INs cleave tDNA phosphodiester bonds that are separated by 6 bp.

**RETROVIRAL IN DOMAIN ORGANIZATION**

Retroviral IN proteins consist of approximately 275-470 amino acid residues. The INs to be discussed in detail in this review amount to 288 (HIV-1), 392 (PFV), 286 (RSV), and 319 (MMTV) residues[25-27]. Retroviral INs comprise three domains common to all genera: The N-terminal domain (NTD), the catalytic core domain (CCD), and the C-terminal domain (CTD)[28-32], which connect to one another *via* flexible linkers that vary in length across the viruses (Figure 2). The NTD adopts a helix-turn-helix fold and harbors two pairs of Zn2+-coordinating histidine and cysteine residues (HHCC motif), which are additionally conserved in retrotransposon INs and are involved in the recognition of the viral LTRs[30,31,33-35]. Accordingly, Zn2+ binding triggers HIV-1 IN multimerization and increases its catalytic activity[36,37]. The CCD adopts an RNase H fold and coordinates two Mg2+ ions *via* the invariant Asp and Glu amino acid residues that comprise the D, DX35E catalytic triad motif[28,29,38-40]. The coordination of Mg2+ ions chemically activates the nucleophiles for 3’-processing (water) as well as for strand transfer (3’-OH groups of vDNA) and destabilizes the respective scissile phosphodiester bonds[41-43]. The CTD is the least conserved among the shared IN domains, however, the tertiary structures of resolved CTDs show similar characteristics: They adopt a Src homology 3 (SH3) fold[44,45], are involved in DNA binding[46], and promote IN multimerization[47,48]. Some retroviruses, namely spuma-, ε- and γ-retroviruses, harbor an additional NTD extension domain (NED) that precedes the NTD[26,40,49] and engages vDNA in the context of the intasome structure[40]. These IN proteins accordingly are larger than their lenti-, α-, β- and δ-retroviral cousins that lack the NED.

**MULTIMERIZATION OF IN**

Numerous biochemical studies revealed that the active form of retroviral IN is a multimer that engages vDNA and tDNA in the confines of a nucleoprotein complex[50-58]. Bacteriophage Mu-mediated PCR footprinting of PICs extracted from infected cells revealed the protection of several hundred bp at the vDNA ends, and the associated complex was termed “intasome” to distinguish it from the larger PICs[59,60]. Subsequently, the intasome term was adopted by structural biologists who constructed and purified distinct, functional IN-DNA complexes capable of efficient concerted integration of two synapsed oligonucleotide vDNA ends, the structures of which were solved by X-ray crystallography[40,43,61-63] or single particle cryo-electron microscopy (EM)[26]. Although retroviral INs have been studied for decades, the 3-dimensional structures of PFV intasomes greatly aided the elucidation of the details of 3’-processing and strand transfer reaction mechanisms[40,43,62].

The “intasome” term today applies to the family of nucleoprotein complexes that are known to mediate retroviral DNA integration (Figure 1), which encompasses the stable synaptic complex (SSC)[43], the cleaved donor complex (CDC) or cleaved intasome[40,43], the target capture complex (TCC)[43,62], and the STC[62,63] (Figure 1). The SSC forms upon IN binding to the vDNA ends[5,40,55,57-60,64,65]. The hydrolytic cleavage of a di- or trinucleotide from each 3’-end marks the transition to the CDC. The TCC forms when the CDC engages tDNA, whereas the STC is formed when the vDNA ends are inserted into tDNA and thus strand transfer is completed[57,58,61-64,66]. The PFV system has importantly afforded high-resolution structures for each of these complexes[40,43,62,63].

**APPROACHES TO STUDY THE THREE-DIMENSIONAL STRUCTURES OF RETROVIRAL IN PROTEINS**

Mechanistic studies of retroviral DNA integration began in earnest in the late 1980s and early 1990s when PICs partially purified from infected cells were shown to promote correct DNA integration *in vitro*[5,14,60,67-70]. Nearly parallel biochemical studies, which utilized purified avian, murine, and human retroviral proteins, importantly showed that IN alone was sufficient to catalyze both the 3’-processing and strand transfer of recombinant vDNA substrates[71-77]. The results of these experiments opened up a new field dedicated to the structural and functional analysis of retroviral INs. Initial work on HIV-1 IN quickly revealed the relatively poor solubility of the full-length enzyme *in vitro*, which limited further biochemical and thus structural characterization[48]. To date, there is no high-resolution structure of a full-length retroviral IN in the absence of DNA, which is likely attributable to the inherent flexibility of the interdomain linkers[78-80]. In essence, the intertwined architecture of IN with vDNA in the context of the intasome complex necessarily “locks down” the inherently flexible enzymes, which afforded platforms for their detailed structural analyses.

**STRUCTURES OF INDIVIDUAL DOMAIN AND TWO-DOMAIN IN CONSTRUCTS**

Initial structures of individual IN domains or two-domain constructs in the absence of DNA (reviewed in[81,82]) (Figure 2) turned out to be challenging in many cases, and were only possible for the HIV-1 IN protein with the help of solubility-enhancing mutations. By systematically replacing hydrophobic residues in the HIV-1 IN CCD, Phe185 was identified as a solubility-limiting residue[83]: Substituting either Lys or His for Phe185 dramatically improved HIV-1 IN protein solubility[48,84]. Although the F185K change enabled the determination of the HIV-1 CCD X-ray structure[85], it conferred a lethal viral phenotype due to deficiencies in virus particle assembly and reverse transcription in addition to defective vDNA integration[48]. Indeed, the vast majority of IN mutations elicit such pleotropic defects on HIV-1 replication (reviewed in[86]). In contrast, the F185H change was tolerated by the virus, and importantly enabled crystallization of the CCD[84,87]. In both cases, the positively charged substituent residue reaches across the CCD dimerization interface and makes a hydrogen bond contact with the main chain carbonyl of Ala105 of the partner IN monomer. The F185K and F185H changes are therefore likely to dramatically increase HIV-1 IN solubility by removing a surface exposed aromatic residue that may nucleate protein aggregation, as well as by enhancing multimerization by adding two hydrogen bonds per IN dimer. Even greater solubility of the HIV-1 CCD was achieved by mutating the tryptophan at position 131 to glutamic acid in the context of the F185K change[88]. Simultaneous to the work on the HIV-1 IN CCD, the X-ray structure of the avian sarcoma virus (ASV) IN CCD was solved[89]. Of note, ASV IN harbors His at the position analogous to Phe185 in HIV-1 IN, and solubility-enhancing mutations accordingly were not required to crystallize the ASV IN CCD. Succeeding structures of HIV-1[88,90-93] and ASV[94-97] IN CCDs elucidated binding sites for metal ion cofactors as well as for early inhibitors. NTD and CTD structures of HIV-1 IN and HIV-2 IN, which were solved by nuclear magnetic resonance spectroscopy[34,35,44,45,98,99], suggested functions of the NTDs in metal ion coordination and the binding of the CTD to vDNA, each of which is required for integration.

Two-domain IN constructs were initially studied as an approach to understand how individual IN domains might interact to form an active nucleoprotein complex. Three different CCD-CTD two-domain structures for HIV-1, simian immunodeficiency virus (SIV), and avian sarcoma-leukosis virus (ASLV) were reported in 2000[100-102]. Each construct harbored at least one solubility-enhancing mutation: C56S, W131D, F139D, F185K, and C280S for HIV-1, F185H for SIV, and F199K for ASLV, the latter two of which are analogous to the F185K change in HIV-1. The HIV-1 CCD-CTD structure revealed an extended α-helix for the CCD-CTD linker region[100]. Whereas the SIV IN CCD-CTD linker could not be traced[101], the RSV IN CCD-CTD linker had a rather extended, non-helical form compared to the HIV-1 IN CCD-CTD linker[102]. The appearance of three different linker configurations in three different IN CCD-CTD constructs led some to suggest that such configurations may result from crystal packing and therefore represent limited physiological relevance[82].

Crystallization of a HIV-1 IN NTD-CCD construct was achieved in 2001 by including W131D, F139D and F185K solubility-enhancing mutations[103]. The resulting X-ray structure revealed possible interactions between two of the NTDs with two CCDs of opposing NTD-CCD molecules, which was of potential physiological relevance due to the fact that it was known from prior biochemical studies that the NTD functioned *in trans* with the CCD[51-53]. However, the inability to trace the NTD-CCD linker regions limited the confidence of this interpretation. Importantly, the domain sharing arrangement suggested by this structure was later confirmed by additional NTD-CCD structures and mutagenesis[104], and ultimately through the elucidation of intasome structures (see below).

**LENTIVIRAL IN-LEDGF CO-CRYSTAL STRUCTURES**

In the early 2000s, a host factor implicated in the nuclear retention of HIV-1 IN, lens epithelium-derived growth factor/transcriptional co-activator p75 (LEDGF/p75), was reported to increase the solubility of HIV-1 IN through its tight binding interaction[105-107]. LEDGF/p75 is a lentiviral-specific IN-binding protein[105,108,109] that tethers vDNA integration to transcriptionally active regions of the host genome (reviewed in[110,111]). LEDGF/p75 engages lentiviral IN *via* its C-terminally located IN-binding domain (IBD)[112]. Although the HIV-1 IN CCD was sufficient for LEDGF/p75 binding, the NTD was required for the high efficiency interaction[107]. LEDGF/p75 binding stabilizes lentiviral IN tetramerization[104,113], which is likely related to its ability to enhance the solubility of the viral proteins.

Crystal structures of lentiviral INs in complex with LEDGF/p75 include an HIV-1 IN F185K CCD construct[114] as well as HIV-2[115] and maedi-visna virus (MVV) IN NTD-CCD two-domain fragments[104]. Though HIV-2 and MVV INs harbor hydrophobic residues at the positions analogous to Phe185 in HIV-1 IN (Phe and Ile, respectively), the favorable solubility properties of lentiviral IN-LEDGF/p75 complexes likely dispelled the need for solubility-enhancing mutations for the crystallization of these constructs. The LEDGF/p75 IBD is a PHAT domain composed of two helix-hairpin-helix motifs[116], with Asp366 at the tip of the N-terminal hairpin nestling into a binding cleft at the HIV-1 IN CCD dimerization interface and contacting the main chain amides of IN residues Glu170 and His171 via hydrogen bonds[114]. A novel class of potent anti-HIV compounds, known as LEDGINs (LEDGF-IN inhibitors) or ALLINIs (allosteric IN inhibitors), structurally mimic the role of Asp366 in their binding to HIV-1 IN, which accounts for their abilities to compete for LEDGF/p75 binding to IN (reviewed in[117]). The two domain NTD-CCD constructs revealed the structural basis for the IN NTD interaction with the LEDGF/p75 IBD, which was ionic in nature. Interestingly, the polarities of the participating salt bridges were functionally reversible, such that HIV-1 particles carrying NTD reverse charge substitutions that were otherwise dead regained partial activity in the presence of the complementary reverse charge LEDGF/p75 partner protein[115,118].

**PFV INTASOME STRUCTURE**

Although the aforementioned individual and two-domain constructs provided insight into retroviral IN function, the field sorely required the structural determination of a functional intasome. The sole class of clinically approved HIV-1 IN inhibitors, known as IN strand transfer inhibitors (INSTIs), displays little if any binding affinity for free IN protein; their clinical target is the IN-vDNA complex[119]. Fortuitously, INSTIs are active against most types of retroviruses[120-122], so intasome structures derived from basically any retroviral genus would have in theory provided a backdrop for understanding the structural basis for INSTI action and the clinical emergence of drug resistance.

Due to the poor solubility of HIV-1 and other early studied retroviral INs, the search for an enzyme with more favorable biochemical properties for *in vitro* experimentation and crystallography was initiated. Though early work had revealed that relatively short oligonucleotide substrates, which modeled the vDNA ends, supported IN 3’ processing and strand transfer activities[72-77], not all enzymes behaved similarly. Most critical for intasome structural biology was the ability for the IN multimer to coordinate the binding of two vDNA ends, and insert these in concerted fashion into opposing strands of tDNA. Critically, PFV IN was discovered to promote efficient concerted integration of oligonucleotide vDNA ends[121]. By contrast, HIV-1 IN had revealed the tendency to insert just one vDNA end at a time[77]. Subsequent modifications of HIV-1 IN expression systems, including protein purification under relatively dilute conditions to prevent IN aggregation[123], or by fusing the small Sso7d DNA binding domain from *Sulfolobus solfataricus* to the IN N-terminus to mimic the NED that naturally exists in PFV IN[124], yielded proteins that supported efficient concerted integration activity. Such modifications might eventually prove useful to characterize HIV-1 intasomes structurally[123,124].

Functional PFV-vDNA complexes assembled by differential salt dialysis migrated as a distinct species on gel filtration columns, and remained intact and active following challenge with high salt concentrations[40]. The initial X-ray crystal structure of the PFV intasome, representing the CDC, was reported in 2010[40] (Figure 3). To date, 37 PFV intasome structures composed of wild-type IN or mutant variants that contain clinically relevant amino acid substitutions have been solved by X-ray crystallography or cryo-EM, representing complexes in the presence of divalent metal ion cofactors, tDNA/nucleosomes, and INSTIs[40,43,62,63,125-130]. The INSTI-bound structures elucidated the mechanism of drug action: the halo-benzyl chemical group common to these compounds assumes the position of the invariant 3’ deoxyadenylate in vDNA with its critical hydroxyl group, thus ejecting the strand transfer nucleophile from the enzyme active site and disarming the nucleoprotein complex[40].

The PFV intasome consists of a tetrameric assembly of IN arranged around a dimer-of-dimers architecture[40] (Figure 3). The inner dimer is composed of two inner monomers (green and pink in Figure 3A), whereas each outer dimer is composed of an inner IN monomer and an outer IN monomer (cyan-green and pink-light grey in Figures 3 and 4). The inner IN monomers make all contacts with vDNA and thus are the catalytic subunits, with each of their constitutive domains mediating vDNA in addition to IN-IN contacts. As previously alluded to, the catalytic subunits are established via a domain sharing mechanism whereby the NTD of each inner IN monomer interacts intimately with the CCD of the opposing IN monomer. The outer IN dimers center around the extensive CCD dimeric interface observed in prior retroviral IN CCD crystal structures[85,87-97]. The CTDs, NTDs, and NEDs of the outer IN monomers are not resolved in the electron density maps, and it is currently unclear what precise role(s) they may play in the catalysis of vDNA integration[131]. It is generally thought that the outer IN monomers mainly play a supportive architectural role to truss the inner IN monomers and vDNA together. As the outer CTDs can contribute to nucleosome binding *in vitro*[130], it seems possible they might play a role during vDNA integration into chromatinized templates, as occurs during virus infection. The NTD-CCD and CCD-CTD linkers, which are only visible for the inner IN monomers in the crystal structures, adopt extended conformations and contact the vDNA[40].

**MMTV AND RSV INTASOME STRUCTURES**

MMTV and RSV intasome structures were recently solved using single-particle cryo-EM[26] and X-ray crystallography[61], respectively. The MMTV intasome was assembled using pre-processed 22 bp vDNA, and thus represents the CDC[26]. The RSV intasome structure by contrast is the STC, which was assembled using a so-called X-mer disintegration substrate[132] where three oligonucleotide strands were annealed together to yield a synapsed complex composed of two 22 bp vDNA branches covalently linked through a central 6 bp stagger to a 38 bp palindromic tDNA[61]. The crystal structure of the PFV STC assembled with its analogous X-mer DNA substrate[63] was virtually identical to the structure that was solved when the CDC integrated into tDNA during crystallogenesis[62], validating the X-mer substrate design approach for RSV STC crystallography.

Although the tetrameric IN4-to-vDNA2 stoichiometry represented by the PFV intasome was generally thought to be evolutionarily conserved across the retroviruses[54,55,57,58], the intasome structures of MMTV and RSV strikingly revealed octameric IN assemblies[26,61] (Figure 3). The MMTV and RSV intasomes comprise a core density region consisting of IN dimers A and B, as well as flanking density regions that consist of IN dimers C and D (Figure 3). Analogous to the PFV structure, core inner IN monomers IN1 and IN3 intimately contact the vDNA ends and are catalytically active, with their NTDs reaching out and contacting the CCDs of the opposing inner monomer (Figure 4). The core structure moreover is primarily supported through CCD dimerization interfaces with outer IN monomers IN2 and IN4. In contrast to PFV, flanking structures in the MMTV and RSV intasomes constitute additional IN dimers, which on their own multimerize primarily through the familiar CCD dimer interface[26,61]. The NTD-CCD linker that is extended in IN1 and IN3 to contact the opposing CCD *in trans* is contracted in the other IN monomers[26]. This observation highlights the necessity for NTD-CCD linker flexibility: Though principally contracted, it must also possess the ability to extend when situated at the IN1 and IN3 positions to support IN catalytic function. In hindsight, it is not surprising that the linker regions in the original HIV-1 IN NTD-CCD structure, which lacked LEDGF/p75 or DNA binding partners, were untraceable[103]. Of note, whereas the crystallographic PFV intasome structure is rather rigid, the flanking dimer regions in the MMTV and RSV intasome structures reveal significant flexibility (Figure 3B). As small angle X-ray scattering analysis of the PFV intasome revealed significant conformational flexibility for the outer subunit NEDs, NTDs, and CTDs of the IN tetramer[79], it is tempting to describe retroviral intasomes as common rigid core structures surrounded by extraneous elements that, although likely to play physiologically relevant roles during virus infection, display marked movement as purified biochemical entities.

The most striking difference between the tetrameric and octameric IN assemblies is the unique function attributed to the CTDs of the flanking dimers in the MMTV and RSV intasome structures. While contacts with vDNA in the PFV structure are restricted to the inner IN1 and IN3 subunits, MMTV and RSV INs donate their CTDs *in trans* to the core region of the intasome[26,61]. The locations of six CTDs, including those of the flanking IN dimers, are conserved in the MMTV and RSV intasomes (Figure 4). The exclusive conformation of the CTDs allows them to tightly associate near the vDNA and assume positions resembling those of the inner PFV CTDs (Figure 4). Biochemical complementation assays revealed that the flanking MMTV IN dimers are crucial for IN catalytic function[26]. Intriguingly, the length of the CCD-CTD linker is quite variable among retroviral INs, amounting to about 50 residues for PFV, but only to 8 residues for MMTV and RSV IN[26] (Figure 2). The extended conformation of the PFV IN 49-mer CTD-CCD linker affords the positioning of IN1 and IN3 CTDs to enable critical contacts with vDNA and tDNA during integration[40,62]. The analogous HIV-1 IN linker, composed of 20 residues (Figure 2), could be stretched to similarly position inner IN monomer CTDs in a molecular model of the HIV-1 intasome based on the PFV structure[133]. However, it is physically impossible for an 8 amino acid region to span the required distance. MMTV and RSV accordingly solve this conundrum by employing additional IN molecules to donate their CTDs to the required positions in the intasome core structure (Figure 4). Hence, retroviral IN CTD-CCD linker length is suggested to be a key determinant for the higher-order architecture of the respective intasome structures[26,61].

**TARGET DNA BINDING AND STRAND TRANSFER**

The integration of vDNA into tDNA does not occur randomly in the host genome, with integration site selection preferences varying among retroviruses (recently reviewed in[134]). Whereas HIV-1 and other lentiviruses favor integration into highly expressed genes that are rich in introns[135-139], the spumavirus PFV avoids active gene regions[130,140,141]. Interestingly, α- and β-retroviruses such as RSV and MMTV are the least selective in integration site selection, displaying patterns that much more closely approach random[138,142,143].

The co-crystallization of the PFV intasome with an oligonucleotide tDNA[62] derived from the PFV consensus integration sequence[121,140] elucidated the mechanism of strand transfer. Whereas crystallization in the absence of Mg2+ or the presence of a dideoxy viral 3’ end led to high-resolution TCC structures, the addition of Mg2+ with the normal vDNA end afforded integration during crystallogenesis, yielding the first high-resolution structure of a retroviral or bacterial transposon STC[62] (Figure 5). The tDNA adopted a highly bent conformation at the PFV DNA insertion sites, with the major groove widened to 26.3 Å and the minor groove compressed to 9.6 Å[62]. This conformation enables the accommodation of the inner IN1 and IN3 D,DX35E catalytic triads to the scissile phosphodiester bonds of tDNA, thus promoting integration[62]. As SN2 transesterification reactions are iso-energetic, they have the potential to reverse direction if chemical leaving groups remain associated with the catalytic active site. Following strand transfer, the newly formed phosphodiester bonds are displaced by 2.3 Å from the IN active sites, effectively suppressing the probability for strand transfer reversal[62]. A similar displacement is described for the tDNA in the RSV intasome[61].

Early studies revealed that retroviral INs prefer chromatinized tDNA templates over naked DNA for integration *in vitro*[144-147], and subsequent work revealed the propensity to similarly target nucleosomes during virus infection[135,148]. PFV IN prefers relatively flexible tDNA sequences for integration[62], and a cryo-EM structure of an intasome-nucleosome complex revealed the same degree of local tDNA distortion can occur on the nucleosome surface during PFV integration[130]. Since spumaviral INs cleave tDNA with a 4 bp stagger, it has been suggested that the degree of tDNA kink has to be greater for spumaviral integration than for viruses that cleave target DNA with a 6 bp stagger, such as the α- and β-retroviruses[149]. Although the IN1 and IN3 catalytic triads of the PFV and MMTV intasomes are superimposable, modeling of tDNA into the MMTV CDC revealed a relatively unbent conformation to accommodate a 6 bp staggered cut as compared to the highly bent tDNA conformation for the 4 bp stagger in the PFV TCC[26] (Figure 5).

The RSV STC harbors a highly bent tDNA conformation despite the fact that RSV IN cleaves the DNA with a 6 bp stagger (Figure 5). Kinks located at the vDNA/tDNA junctions of the RSV intasome provoke a 20 Å shift in the helical axis, leading to an overall tDNA twist[61]. Hence, the tDNA conformation in the RSV STC differs significantly from the tDNA conformation in the PFV structure (Figure 5) and also from the relatively unbent tDNA confirmation in the MMTV TCC model[26]. These observations suggest potentially different modes of integration into nucleosomal DNA among the studied viruses. Whereas PFV and RSV are predicted to target chromatinized DNA during virus infection, MMTV was unique among a study of 10 exogenous retroviruses for its apparent avoidance of nucleosomal DNA *in vivo*[149]. Elucidation of high-resolution MMTV STC/TCC structures will help to illuminate the degree of tDNA bending that occurs during MMTV integration.

Based on the variety of tDNA structural properties that influence target site selectivity, including bendability[62,149-152], major groove widening, and nucleosomal packaging[144-147,153,154], retroviral INs can be classified as shape-readout DNA binding proteins[155]. DNA minicircles, which mimic nucleosome-induced tDNA circularization in the absence of histones, represent a relatively new tool to tease out physiologically-relevant influences of tDNA structure on integration site selectivity *in vitro*, and the roles of IN-binding cofactors such as LEDGF/p75[156].

**CONCLUSION**

The study of retroviral integration has come a long way since its beginnings in the late 1970s. The relatively large repertoire of individual and two-domain retroviral IN structures that were solved initially has since expanded to a set of high-resolution intasome structures, including those from the spumavirus PFV, β-retrovirus MMTV, and α-retrovirus RSV. To date, the plethora of PFV intasome structures represents a remarkable advance for the field of retroviral integration. Not only have they elucidated the mechanism of INSTI action, they provide high-resolution structures of the entire set of complexes (SSC, CDC, TCC, and STC) that mediate retroviral DNA integration[40,43,62,63].

The recently emerged octameric intasome structures of MMTV[26] and RSV[61] reveal an unexpected evolutionary diversity among retroviruses. As the intasomal core is conserved among the three studied retroviruses, the utilization of flanking dimers to complete the functional MMTV and RSV intasome structures represents a remarkable example of convergent evolution of the DNA integration apparatus[26,61]. Considering CCD-CTD linker length as a predictor of the state of IN multimerization within functional intasomes[26], it remains to be investigated whether retroviral INs with intermediary linker lengths, including those of HIV-1 and the δ-retrovirus human T-cell lymphotropic virus, which harbor 20 and 19 residues, respectively[26], will reveal tetrameric, octameric, or perhaps even higher-order IN assemblies.

Motivated by the recent advances in the intasome field, new IN-DNA complexes are currently being investigated in various laboratories, including those derived from lentiviruses. The emergence of new three-dimensional intasome structures will help to model novel interactions between HIV-1 IN and DNA, and thus should reveal new insights into the mechanisms of emergence of drug resistance to clinical INSTIs.

**REFERENCES**

1 **Iordanskiy S**, Bukrinsky M. Reverse transcription complex: the key player of the early phase of HIV replication. *Future Virol* 2007; **2**: 49-64 [PMID: 23658595 DOI: 10.2217/17460794.2.1.49]

2 **Bowerman B**, Brown PO, Bishop JM, Varmus HE. A nucleoprotein complex mediates the integration of retroviral DNA. *Genes Dev* 1989; **3**: 469-478 [PMID: 2721960 DOI: 10.1101/gad.3.4.469]

3 **Farnet CM**, Haseltine WA. Determination of viral proteins present in the human immunodeficiency virus type 1 preintegration complex. *J Virol* 1991; **65**: 1910-1915 [PMID: 2002549]

4 **Bukrinsky MI**, Sharova N, McDonald TL, Pushkarskaya T, Tarpley WG, Stevenson M. Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. *Proc Natl Acad Sci USA* 1993; **90**: 6125-6129 [PMID: 7687060 DOI: 10.1073/pnas.90.13.6125]

5 **Miller MD**, Farnet CM, Bushman FD. Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition. *J Virol* 1997; **71**: 5382-5390 [PMID: 9188609]

6 **Raghavendra NK**, Shkriabai N, Graham RLj, Hess S, Kvaratskhelia M, Wu L. Identification of host proteins associated with HIV-1 preintegration complexes isolated from infected CD4+ cells. *Retrovirology* 2010; **7**: 66 [PMID: 20698996 DOI: 10.1186/1742-4690-7-66]

7 **Schweitzer CJ**, Jagadish T, Haverland N, Ciborowski P, Belshan M. Proteomic analysis of early HIV-1 nucleoprotein complexes. *J Proteome Res* 2013; **12**: 559-572 [PMID: 23282062 DOI: 10.1021/pr300869h]

8 **Vande Woude GF**, Oskarsson M, Enquist LW, Nomura S, Sullivan M, Fischinger PJ. Cloning of integrated Moloney sarcoma proviral DNA sequences in bacteriophage lambda. *Proc Natl Acad Sci USA* 1979; **76**: 4464-4468 [PMID: 159456 DOI: 10.1073/pnas.76.9.4464]

9 **Van Beveren C**, Goddard JG, Berns A, Verma IM. Structure of Moloney murine leukemia viral DNA: nucleotide sequence of the 5' long terminal repeat and adjacent cellular sequences. *Proc Natl Acad Sci USA* 1980; **77**: 3307-3311 [PMID: 6251455 DOI: 10.1073/pnas.77.6.3307]

10 **Ju G**, Skalka AM. Nucleotide sequence analysis of the long terminal repeat (LTR) of avian retroviruses: structural similarities with transposable elements. *Cell* 1980; **22**: 379-386 [PMID: 6256079 DOI: 10.1016/0092-8674(80)90348-7]

11 **Engelman A**, Mizuuchi K, Craigie R. HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer. *Cell* 1991; **67**: 1211-1221 [PMID: 1760846 DOI: 10.1016/0092-8674(91)90297-C]

12 **Pauza CD**. Two bases are deleted from the termini of HIV-1 linear DNA during integrative recombination. *Virology* 1990; **179**: 886-889 [PMID: 2238479 DOI: 10.1016/0042-6822(90)90161-J]

13 **Roth MJ**, Schwartzberg PL, Goff SP. Structure of the termini of DNA intermediates in the integration of retroviral DNA: dependence on IN function and terminal DNA sequence. *Cell* 1989; **58**: 47-54 [PMID: 2546673 DOI: 10.1016/0092-8674(89)90401-7]

14 **Lee YM**, Coffin JM. Relationship of avian retrovirus DNA synthesis to integration in vitro. *Mol Cell Biol* 1991; **11**: 1419-1430 [PMID: 1847499 DOI: 10.1128/MCB.11.3.1419]

15 **Fujiwara T**, Mizuuchi K. Retroviral DNA integration: structure of an integration intermediate. *Cell* 1988; **54**: 497-504 [PMID: 3401925 DOI: 10.1016/0092-8674(88)90071-2]

16 **Brown PO**, Bowerman B, Varmus HE, Bishop JM. Retroviral integration: structure of the initial covalent product and its precursor, and a role for the viral IN protein. *Proc Natl Acad Sci USA* 1989; **86**: 2525-2529 [PMID: 2539592 DOI: 10.1073/pnas.86.8.2525]

17 **Lesbats P**, Engelman AN, Cherepanov P. Retroviral DNA Integration. *Chem Rev* 2016; **116**:12730-12757 [PMID: 27198982 DOI: 10.1021/acs.chemrev.6b00125]

18 **Schweizer M**, Fleps U, Jäckle A, Renne R, Turek R, Neumann-Haefelin D. Simian foamy virus type 3 (SFV-3) in latently infected Vero cells: reactivation by demethylation of proviral DNA. *Virology* 1993; **192**: 663-666 [PMID: 8380669 DOI: 10.1006/viro.1993.1084]

19 **Neves M**, Périès J, Saïb A. Study of human foamy virus proviral integration in chronically infected murine cells. *Res Virol* 1998; **149**: 393-401 [PMID: 9923015 DOI: 10.1016/S0923-2516(99)80007-7]

20 **Vincent KA**, York-Higgins D, Quiroga M, Brown PO. Host sequences flanking the HIV provirus. *Nucleic Acids Res* 1990; **18**: 6045-6047 [PMID: 2235486 DOI: 10.1093/nar/18.20.6045]

21 **Vink C**, Groenink M, Elgersma Y, Fouchier RA, Tersmette M, Plasterk RH. Analysis of the junctions between human immunodeficiency virus type 1 proviral DNA and human DNA. *J Virol* 1990; **64**: 5626-5627 [PMID: 2214029]

22 **Majors JE**, Varmus HE. Nucleotide sequences at host-proviral junctions for mouse mammary tumour virus. *Nature* 1981; **289**: 253-258 [PMID: 6256658 DOI: 10.1038/289253a0]

23 **Hishinuma F**, DeBona PJ, Astrin S, Skalka AM. Nucleotide sequence of acceptor site and termini of integrated avian endogenous provirus ev1: integration creates a 6 bp repeat of host DNA. *Cell* 1981; **23**: 155-164 [PMID: 6260371 DOI: 10.1016/0092-8674(81)90280-4]

24 **Hughes SH**, Mutschler A, Bishop JM, Varmus HE. A Rous sarcoma virus provirus is flanked by short direct repeats of a cellular DNA sequence present in only one copy prior to integration. *Proc Natl Acad Sci USA* 1981; **78**: 4299-4303 [PMID: 6270669 DOI: 10.1073/pnas.78.7.4299]

25 **Grandgenett DP**, Pandey KK, Bera S, Aihara H. Multifunctional facets of retrovirus integrase. *World J Biol Chem* 2015; **6**: 83-94 [PMID: 26322168 DOI: 10.4331/wjbc.v6.i3.83]

26 **Ballandras-Colas A**, Brown M, Cook NJ, Dewdney TG, Demeler B, Cherepanov P, Lyumkis D, Engelman AN. Cryo-EM reveals a novel octameric integrase structure for betaretroviral intasome function. *Nature* 2016; **530**: 358-361 [PMID: 26887496 DOI: 10.1038/nature16955]

27 **Andrake MD**, Skalka AM. Retroviral Integrase: Then and Now. *Annu Rev Virol* 2015; **2**: 241-264 [PMID: 26958915 DOI: 10.1146/annurev-virology-100114-055043]

28 **Kulkosky J**, Jones KS, Katz RA, Mack JP, Skalka AM. Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases. *Mol Cell Biol* 1992; **12**: 2331-2338 [PMID: 1314954 DOI: 10.1128/MCB.12.5.2331]

29 **Engelman A**, Craigie R. Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro. *J Virol* 1992; **66**: 6361-6369 [PMID: 1404595]

30 **Burke CJ**, Sanyal G, Bruner MW, Ryan JA, LaFemina RL, Robbins HL, Zeft AS, Middaugh CR, Cordingley MG. Structural implications of spectroscopic characterization of a putative zinc finger peptide from HIV-1 integrase. *J Biol Chem* 1992; **267**: 9639-9644 [PMID: 1577801]

31 **Bushman FD**, Engelman A, Palmer I, Wingfield P, Craigie R. Domains of the integrase protein of human immunodeficiency virus type 1 responsible for polynucleotidyl transfer and zinc binding. *Proc Natl Acad Sci USA* 1993; **90**: 3428-3432 [PMID: 8386373 DOI: 10.1073/pnas.90.8.3428]

32 **Woerner AM**, Klutch M, Levin JG, Marcus-Sekura CJ. Localization of DNA binding activity of HIV-1 integrase to the C-terminal half of the protein. *AIDS Res Hum Retroviruses* 1992; **8**: 297-304 [PMID: 1540416 DOI: 10.1089/aid.1992.8.297]

33 **Khan E**, Mack JP, Katz RA, Kulkosky J, Skalka AM. Retroviral integrase domains: DNA binding and the recognition of LTR sequences. *Nucleic Acids Res* 1991; **19**: 851-860 [PMID: 1850126 DOI: 10.1093/nar/19.6.1358]

34 **Cai M**, Zheng R, Caffrey M, Craigie R, Clore GM, Gronenborn AM. Solution structure of the N-terminal zinc binding domain of HIV-1 integrase. *Nat Struct Biol* 1997; **4**: 567-577 [PMID: 9228950 DOI: 10.1038/nsb0797-567]

35 **Eijkelenboom AP**, van den Ent FM, Vos A, Doreleijers JF, Hård K, Tullius TD, Plasterk RH, Kaptein R, Boelens R. The solution structure of the amino-terminal HHCC domain of HIV-2 integrase: a three-helix bundle stabilized by zinc. *Curr Biol* 1997; **7**: 739-746 [PMID: 9368756 DOI: 10.1016/S0960-9822(06)00332-0]

36 **Zheng R**, Jenkins TM, Craigie R. Zinc folds the N-terminal domain of HIV-1 integrase, promotes multimerization, and enhances catalytic activity. *Proc Natl Acad Sci USA* 1996; **93**: 13659-13664 [PMID: 8942990 DOI: 10.1073/pnas.93.24.13659]

37 **Lee SP**, Han MK. Zinc stimulates Mg2+-dependent 3'-processing activity of human immunodeficiency virus type 1 integrase in vitro. *Biochemistry* 1996; **35**: 3837-3844 [PMID: 8620007 DOI: 10.1021/bi952056p]

38 **Drelich M**, Wilhelm R, Mous J. Identification of amino acid residues critical for endonuclease and integration activities of HIV-1 IN protein in vitro. *Virology* 1992; **188**: 459-468 [PMID: 1585629 DOI: 10.1016/0042-6822(92)90499-F]

39 **Leavitt AD**, Shiue L, Varmus HE. Site-directed mutagenesis of HIV-1 integrase demonstrates differential effects on integrase functions in vitro. *J Biol Chem* 1993; **268**: 2113-2119 [PMID: 8420982]

40 **Hare S**, Gupta SS, Valkov E, Engelman A, Cherepanov P. Retroviral intasome assembly and inhibition of DNA strand transfer. *Nature* 2010; **464**: 232-236 [PMID: 20118915 DOI: 10.1038/nature08784]

41 **Mizuuchi K**. Polynucleotidyl transfer reactions in transpositional DNA recombination. *J Biol Chem* 1992; **267**: 21273-21276 [PMID: 1383220]

42 **Yang W**, Lee JY, Nowotny M. Making and breaking nucleic acids: two-Mg2+-ion catalysis and substrate specificity. *Mol Cell* 2006; **22**: 5-13 [PMID: 16600865 DOI: 10.1016/j.molcel.2006.03.013]

43 **Hare S**, Maertens GN, Cherepanov P. 3'-processing and strand transfer catalysed by retroviral integrase in crystallo. *EMBO J* 2012; **31**: 3020-3028 [PMID: 22580823 DOI: 10.1038/emboj.2012.118]

44 **Eijkelenboom AP**, Lutzke RA, Boelens R, Plasterk RH, Kaptein R, Hård K. The DNA-binding domain of HIV-1 integrase has an SH3-like fold. *Nat Struct Biol* 1995; **2**: 807-810 [PMID: 7552753 DOI: 10.1038/nsb0995-807]

45 **Lodi PJ**, Ernst JA, Kuszewski J, Hickman AB, Engelman A, Craigie R, Clore GM, Gronenborn AM. Solution structure of the DNA binding domain of HIV-1 integrase. *Biochemistry* 1995; **34**: 9826-9833 [PMID: 7632683 DOI: 10.1021/bi00031a002]

46 **Engelman A**, Hickman AB, Craigie R. The core and carboxyl-terminal domains of the integrase protein of human immunodeficiency virus type 1 each contribute to nonspecific DNA binding. *J Virol* 1994; **68**: 5911-5917 [PMID: 8057470]

47 **Andrake MD**, Skalka AM. Multimerization determinants reside in both the catalytic core and C terminus of avian sarcoma virus integrase. *J Biol Chem* 1995; **270**: 29299-29306 [PMID: 7493962 DOI: 10.1074/jbc.270.49.29299]

48 **Jenkins TM**, Engelman A, Ghirlando R, Craigie R. A soluble active mutant of HIV-1 integrase: involvement of both the core and carboxyl-terminal domains in multimerization. *J Biol Chem* 1996; **271**: 7712-7718 [PMID: 8631811 DOI: 10.1074/jbc.271.13.7712]

49 **Krishnan L**, Engelman A. Retroviral integrase proteins and HIV-1 DNA integration. *J Biol Chem* 2012; **287**: 40858-40866 [PMID: 23043109 DOI: 10.1074/jbc.R112.397760]

50 **Jones KS**, Coleman J, Merkel GW, Laue TM, Skalka AM. Retroviral integrase functions as a multimer and can turn over catalytically. *J Biol Chem* 1992; **267**: 16037-16040 [PMID: 1322888]

51 **Engelman A**, Bushman FD, Craigie R. Identification of discrete functional domains of HIV-1 integrase and their organization within an active multimeric complex. *EMBO J* 1993; **12**: 3269-3275 [PMID: 8344264]

52 **van Gent DC**, Vink C, Groeneger AA, Plasterk RH. Complementation between HIV integrase proteins mutated in different domains. *EMBO J* 1993; **12**: 3261-3267 [PMID: 8344263]

53 **Jonsson CB**, Donzella GA, Gaucan E, Smith CM, Roth MJ. Functional domains of Moloney murine leukemia virus integrase defined by mutation and complementation analysis. *J Virol* 1996; **70**: 4585-4597 [PMID: 8676485]

54 **Bao KK**, Wang H, Miller JK, Erie DA, Skalka AM, Wong I. Functional oligomeric state of avian sarcoma virus integrase. *J Biol Chem* 2003; **278**: 1323-1327 [PMID: 12446721 DOI: 10.1074/jbc.C200550200]

55 **Faure A**, Calmels C, Desjobert C, Castroviejo M, Caumont-Sarcos A, Tarrago-Litvak L, Litvak S, Parissi V. HIV-1 integrase crosslinked oligomers are active in vitro. *Nucleic Acids Res* 2005; **33**: 977-986 [PMID: 15718297 DOI: 10.1093/nar/gki241]

56 **Guiot E**, Carayon K, Delelis O, Simon F, Tauc P, Zubin E, Gottikh M, Mouscadet JF, Brochon JC, Deprez E. Relationship between the oligomeric status of HIV-1 integrase on DNA and enzymatic activity. *J Biol Chem* 2006; **281**: 22707-22719 [PMID: 16774912 DOI: 10.1074/jbc.M602198200]

57 **Li M**, Mizuuchi M, Burke TR, Craigie R. Retroviral DNA integration: reaction pathway and critical intermediates. *EMBO J* 2006; **25**: 1295-1304 [PMID: 16482214 DOI: 10.1038/sj.emboj.7601005]

58 **Bera S**, Pandey KK, Vora AC, Grandgenett DP. Molecular Interactions between HIV-1 integrase and the two viral DNA ends within the synaptic complex that mediates concerted integration. *J Mol Biol* 2009; **389**: 183-198 [PMID: 19362096 DOI: 10.1016/j.jmb.2009.04.007]

59 **Wei SQ**, Mizuuchi K, Craigie R. A large nucleoprotein assembly at the ends of the viral DNA mediates retroviral DNA integration. *EMBO J* 1997; **16**: 7511-7520 [PMID: 9405379 DOI: 10.1093/emboj/16.24.7511]

60 **Chen H**, Wei SQ, Engelman A. Multiple integrase functions are required to form the native structure of the human immunodeficiency virus type I intasome. *J Biol Chem* 1999; **274**: 17358-17364 [PMID: 10358097 DOI: 10.1074/jbc.274.24.17358]

61 **Yin Z**, Shi K, Banerjee S, Pandey KK, Bera S, Grandgenett DP, Aihara H. Crystal structure of the Rous sarcoma virus intasome. *Nature* 2016; **530**: 362-366 [PMID: 26887497 DOI: 10.1038/nature16950]

62 **Maertens GN**, Hare S, Cherepanov P. The mechanism of retroviral integration from X-ray structures of its key intermediates. *Nature* 2010; **468**: 326-329 [PMID: 21068843 DOI: 10.1038/nature09517]

63 **Yin Z**, Lapkouski M, Yang W, Craigie R. Assembly of prototype foamy virus strand transfer complexes on product DNA bypassing catalysis of integration. *Protein Sci* 2012; **21**: 1849-1857 [PMID: 23011895 DOI: 10.1002/pro.2166]

64 **Kotova S**, Li M, Dimitriadis EK, Craigie R. Nucleoprotein intermediates in HIV-1 DNA integration visualized by atomic force microscopy. *J Mol Biol* 2010; **399**: 491-500 [PMID: 20416324 DOI: 10.1016/j.jmb.2010.04.026]

65 **Kessl JJ**, Li M, Ignatov M, Shkriabai N, Eidahl JO, Feng L, Musier-Forsyth K, Craigie R, Kvaratskhelia M. FRET analysis reveals distinct conformations of IN tetramers in the presence of viral DNA or LEDGF/p75. *Nucleic Acids Res* 2011; **39**: 9009-9022 [PMID: 21771857 DOI: 10.1093/nar/gkr581]

66 **Pandey KK**, Bera S, Zahm J, Vora A, Stillmock K, Hazuda D, Grandgenett DP. Inhibition of human immunodeficiency virus type 1 concerted integration by strand transfer inhibitors which recognize a transient structural intermediate. *J Virol* 2007; **81**: 12189-12199 [PMID: 17804497 DOI: 10.1128/JVI.02863-06]

67 **Brown PO**, Bowerman B, Varmus HE, Bishop JM. Correct integration of retroviral DNA in vitro. *Cell* 1987; **49**: 347-356 [PMID: 3032450 DOI: 10.1016/0092-8674(87)90287-X]

68 **Farnet CM**, Haseltine WA. Integration of human immunodeficiency virus type 1 DNA in vitro. *Proc Natl Acad Sci USA* 1990; **87**: 4164-4168 [PMID: 2349226 DOI: 10.1073/pnas.87.11.4164]

69 **Ellison V**, Abrams H, Roe T, Lifson J, Brown P. Human immunodeficiency virus integration in a cell-free system. *J Virol* 1990; **64**: 2711-2715 [PMID: 2335814]

70 **Wei SQ**, Mizuuchi K, Craigie R. Footprints on the viral DNA ends in moloney murine leukemia virus preintegration complexes reflect a specific association with integrase. *Proc Natl Acad Sci USA* 1998; **95**: 10535-10540 [PMID: 9724738 DOI: 10.1073/pnas.95.18.10535]

71 **Bushman FD**, Fujiwara T, Craigie R. Retroviral DNA integration directed by HIV integration protein in vitro. *Science* 1990; **249**: 1555-1558 [PMID: 2171144 DOI: 10.1126/science.2171144]

72 **Katzman M**, Katz RA, Skalka AM, Leis J. The avian retroviral integration protein cleaves the terminal sequences of linear viral DNA at the in vivo sites of integration. *J Virol* 1989; **63**: 5319-5327 [PMID: 2555556]

73 **Katz RA**, Merkel G, Kulkosky J, Leis J, Skalka AM. The avian retroviral IN protein is both necessary and sufficient for integrative recombination in vitro. *Cell* 1990; **63**: 87-95 [PMID: 2170022 DOI: 10.1016/0092-8674(90)90290-U]

74 **Pahl A**, Flügel RM. Endonucleolytic cleavages and DNA-joining activities of the integration protein of human foamy virus. *J Virol* 1993; **67**: 5426-5434 [PMID: 7688824]

75 **Sherman PA**, Fyfe JA. Human immunodeficiency virus integration protein expressed in Escherichia coli possesses selective DNA cleaving activity. *Proc Natl Acad Sci USA* 1990; **87**: 5119-5123 [PMID: 2164223 DOI: 10.1073/pnas.87.13.5119]

76 **Craigie R**, Fujiwara T, Bushman F. The IN protein of Moloney murine leukemia virus processes the viral DNA ends and accomplishes their integration in vitro. *Cell* 1990; **62**: 829-837 [PMID: 2167180 DOI: 10.1016/0092-8674(90)90126-Y]

77 **Bushman FD**, Craigie R. Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA. *Proc Natl Acad Sci USA* 1991; **88**: 1339-1343 [PMID: 1847518 DOI: 10.1073/pnas.88.4.1339]

78 **Jaskolski M**, Alexandratos JN, Bujacz G, Wlodawer A. HIV-1 Integrase. Neamati N, editor. Hoboken (NJ): John Wiley & Sons, Inc., 2011: 35-49 [DOI: 10.1002/9781118015377.ch4]

79 **Gupta K**, Curtis JE, Krueger S, Hwang Y, Cherepanov P, Bushman FD, Van Duyne GD. Solution conformations of prototype foamy virus integrase and its stable synaptic complex with U5 viral DNA. *Structure* 2012; **20**: 1918-1928 [PMID: 23000384 DOI: 10.1016/j.str.2012.08.023]

80 **Zhao Z**, McKee CJ, Kessl JJ, Santos WL, Daigle JE, Engelman A, Verdine G, Kvaratskhelia M. Subunit-specific protein footprinting reveals significant structural rearrangements and a role for N-terminal Lys-14 of HIV-1 Integrase during viral DNA binding. *J Biol Chem* 2008; **283**: 5632-5641 [PMID: 18093980 DOI: 10.1074/jbc.M705241200]

81 **Jaskolski M**, Alexandratos JN, Bujacz G, Wlodawer A. Piecing together the structure of retroviral integrase, an important target in AIDS therapy. *FEBS J* 2009; **276**: 2926-2946 [PMID: 19490099 DOI: 10.1111/j.1742-4658.2009.07009.x]

82 **Li X**, Krishnan L, Cherepanov P, Engelman A. Structural biology of retroviral DNA integration. *Virology* 2011; **411**: 194-205 [PMID: 21216426 DOI: 10.1016/j.virol.2010.12.008]

83 **Jenkins TM**, Hickman AB, Dyda F, Ghirlando R, Davies DR, Craigie R. Catalytic domain of human immunodeficiency virus type 1 integrase: identification of a soluble mutant by systematic replacement of hydrophobic residues. *Proc Natl Acad Sci USA* 1995; **92**: 6057-6061 [PMID: 7597080 DOI: 10.1073/pnas.92.13.6057]

84 **Engelman A**, Liu Y, Chen H, Farzan M, Dyda F. Structure-based mutagenesis of the catalytic domain of human immunodeficiency virus type 1 integrase. *J Virol* 1997; **71**: 3507-3514 [PMID: 9094622]

85 **Dyda F**, Hickman AB, Jenkins TM, Engelman A, Craigie R, Davies DR. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. *Science* 1994; **266**: 1981-1986 [PMID: 7801124 DOI: 10.1126/science.7801124]

86 **Engelman A**. In vivo analysis of retroviral integrase structure and function. *Adv Virus Res* 1999; **52**: 411-426 [PMID: 10384245 DOI: 10.1016/S0065-3527(08)60309-7]

87 **Bujacz G**, Alexandratos J, Qing ZL, Clément-Mella C, Wlodawer A. The catalytic domain of human immunodeficiency virus integrase: ordered active site in the F185H mutant. *FEBS Lett* 1996; **398**: 175-178 [PMID: 8977101 DOI: 10.1016/S0014-5793(96)01236-7]

88 **Goldgur Y**, Craigie R, Cohen GH, Fujiwara T, Yoshinaga T, Fujishita T, Sugimoto H, Endo T, Murai H, Davies DR. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. *Proc Natl Acad Sci USA* 1999; **96**: 13040-13043 [PMID: 10557269 DOI: 10.1073/pnas.96.23.13040]

89 **Bujacz G**, Jaskólski M, Alexandratos J, Wlodawer A, Merkel G, Katz RA, Skalka AM. High-resolution structure of the catalytic domain of avian sarcoma virus integrase. *J Mol Biol* 1995; **253**: 333-346 [PMID: 7563093 DOI: 10.1006/jmbi.1995.0556]

90 **Goldgur Y**, Dyda F, Hickman AB, Jenkins TM, Craigie R, Davies DR. Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium. *Proc Natl Acad Sci USA* 1998; **95**: 9150-9154 [PMID: 9689049 DOI: 10.1073/pnas.95.16.9150]

91 **Greenwald J**, Le V, Butler SL, Bushman FD, Choe S. The mobility of an HIV-1 integrase active site loop is correlated with catalytic activity. *Biochemistry* 1999; **38**: 8892-8898 [PMID: 10413462 DOI: 10.1021/bi9907173]

92 **Maignan S**, Guilloteau JP, Zhou-Liu Q, Clément-Mella C, Mikol V. Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases. *J Mol Biol* 1998; **282**: 359-368 [PMID: 9735293 DOI: 10.1006/jmbi.1998.2002]

93 **Molteni V**, Greenwald J, Rhodes D, Hwang Y, Kwiatkowski W, Bushman FD, Siegel JS, Choe S. Identification of a small-molecule binding site at the dimer interface of the HIV integrase catalytic domain. *Acta Crystallogr D Biol Crystallogr* 2001; **57**: 536-544 [PMID: 11264582 DOI: 10.1107/S0907444901001652]

94 **Bujacz G**, Alexandratos J, Wlodawer A, Merkel G, Andrake M, Katz RA, Skalka AM. Binding of different divalent cations to the active site of avian sarcoma virus integrase and their effects on enzymatic activity. *J Biol Chem* 1997; **272**: 18161-18168 [PMID: 9218451 DOI: 10.1074/jbc.272.29.18161]

95 **Bujacz G**, Jaskólski M, Alexandratos J, Wlodawer A, Merkel G, Katz RA, Skalka AM. The catalytic domain of avian sarcoma virus integrase: conformation of the active-site residues in the presence of divalent cations. *Structure* 1996; **4**: 89-96 [PMID: 8805516 DOI: 10.1016/S0969-2126(96)00012-3]

96 **Lubkowski J**, Yang F, Alexandratos J, Merkel G, Katz RA, Gravuer K, Skalka AM, Wlodawer A. Structural basis for inactivating mutations and pH-dependent activity of avian sarcoma virus integrase. *J Biol Chem* 1998; **273**: 32685-32689 [PMID: 9830010 DOI: 10.1074/jbc.273.49.32685]

97 **Lubkowski J**, Dauter Z, Yang F, Alexandratos J, Merkel G, Skalka AM, Wlodawer A. Atomic resolution structures of the core domain of avian sarcoma virus integrase and its D64N mutant. *Biochemistry* 1999; **38**: 13512-13522 [PMID: 10521258 DOI: 10.1021/bi995092n]

98 **Eijkelenboom AP**, Sprangers R, Hård K, Puras Lutzke RA, Plasterk RH, Boelens R, Kaptein R. Refined solution structure of the C-terminal DNA-binding domain of human immunovirus-1 integrase. *Proteins* 1999; **36**: 556-564 [PMID: 10450096 DOI: 10.1002/(SICI)1097-0134(19990901)36: 4<556: : AID-PROT18>3.0.CO; 2-6]

99 **Eijkelenboom AP**, van den Ent FM, Wechselberger R, Plasterk RH, Kaptein R, Boelens R. Refined solution structure of the dimeric N-terminal HHCC domain of HIV-2 integrase. *J Biomol NMR* 2000; **18**: 119-128 [PMID: 11101216 DOI: 10.1023/A: 1008342312269]

100 **Chen JC**, Krucinski J, Miercke LJ, Finer-Moore JS, Tang AH, Leavitt AD, Stroud RM. Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. *Proc Natl Acad Sci USA* 2000; **97**: 8233-8238 [PMID: 10890912 DOI: 10.1073/pnas.150220297]

101 **Chen Z**, Yan Y, Munshi S, Li Y, Zugay-Murphy J, Xu B, Witmer M, Felock P, Wolfe A, Sardana V, Emini EA, Hazuda D, Kuo LC. X-ray structure of simian immunodeficiency virus integrase containing the core and C-terminal domain (residues 50-293)--an initial glance of the viral DNA binding platform. *J Mol Biol* 2000; **296**: 521-533 [PMID: 10669606 DOI: 10.1006/jmbi.1999.3451]

102 **Yang ZN**, Mueser TC, Bushman FD, Hyde CC. Crystal structure of an active two-domain derivative of Rous sarcoma virus integrase. *J Mol Biol* 2000; **296**: 535-548 [PMID: 10669607 DOI: 10.1006/jmbi.1999.3463]

103 **Wang JY**, Ling H, Yang W, Craigie R. Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein. *EMBO J* 2001; **20**: 7333-7343 [PMID: 11743009 DOI: 10.1093/emboj/20.24.7333]

104 **Hare S**, Di Nunzio F, Labeja A, Wang J, Engelman A, Cherepanov P. Structural basis for functional tetramerization of lentiviral integrase. *PLoS Pathog* 2009; **5**: e1000515 [PMID: 19609359 DOI: 10.1371/journal.ppat.1000515]

105 **Busschots K**, Vercammen J, Emiliani S, Benarous R, Engelborghs Y, Christ F, Debyser Z. The interaction of LEDGF/p75 with integrase is lentivirus-specific and promotes DNA binding. *J Biol Chem* 2005; **280**: 17841-17847 [PMID: 15749713 DOI: 10.1074/jbc.M411681200]

106 **Cherepanov P**, Maertens G, Proost P, Devreese B, Van Beeumen J, Engelborghs Y, De Clercq E, Debyser Z. HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. *J Biol Chem* 2003; **278**: 372-381 [PMID: 12407101 DOI: 10.1074/jbc.M209278200]

107 **Maertens G**, Cherepanov P, Pluymers W, Busschots K, De Clercq E, Debyser Z, Engelborghs Y. LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. *J Biol Chem* 2003; **278**: 33528-33539 [PMID: 12796494 DOI: 10.1074/jbc.M303594200]

108 **Cherepanov P**. LEDGF/p75 interacts with divergent lentiviral integrases and modulates their enzymatic activity in vitro. *Nucleic Acids Res* 2007; **35**: 113-124 [PMID: 17158150 DOI: 10.1093/nar/gkl885]

109 **Llano M**, Vanegas M, Fregoso O, Saenz D, Chung S, Peretz M, Poeschla EM. LEDGF/p75 determines cellular trafficking of diverse lentiviral but not murine oncoretroviral integrase proteins and is a component of functional lentiviral preintegration complexes. *J Virol* 2004; **78**: 9524-9537 [PMID: 15308744 DOI: 10.1128/jvi.78.17.9524-9537.2004]

110 **Engelman A**, Cherepanov P. The lentiviral integrase binding protein LEDGF/p75 and HIV-1 replication. *PLoS Pathog* 2008; **4**: e1000046 [PMID: 18369482 DOI: 10.1371/journal.ppat.1000046]

111 **Poeschla EM**. Integrase, LEDGF/p75 and HIV replication. *Cell Mol Life Sci* 2008; **65**: 1403-1424 [PMID: 18264802 DOI: 10.1007/s00018-008-7540-5]

112 **Cherepanov P**, Devroe E, Silver PA, Engelman A. Identification of an evolutionarily conserved domain in human lens epithelium-derived growth factor/transcriptional co-activator p75 (LEDGF/p75) that binds HIV-1 integrase. *J Biol Chem* 2004; **279**: 48883-48892 [PMID: 15371438 DOI: 10.1074/jbc.M406307200]

113 **McKee CJ**, Kessl JJ, Shkriabai N, Dar MJ, Engelman A, Kvaratskhelia M. Dynamic modulation of HIV-1 integrase structure and function by cellular lens epithelium-derived growth factor (LEDGF) protein. *J Biol Chem* 2008; **283**: 31802-31812 [PMID: 18801737 DOI: 10.1074/jbc.M805843200]

114 **Cherepanov P**, Ambrosio AL, Rahman S, Ellenberger T, Engelman A. Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. *Proc Natl Acad Sci USA* 2005; **102**: 17308-17313 [PMID: 16260736 DOI: 10.1073/pnas.0506924102]

115 **Hare S**, Shun MC, Gupta SS, Valkov E, Engelman A, Cherepanov P. A novel co-crystal structure affords the design of gain-of-function lentiviral integrase mutants in the presence of modified PSIP1/LEDGF/p75. *PLoS Pathog* 2009; **5**: e1000259 [PMID: 19132083 DOI: 10.1371/journal.ppat.1000259]

116 **Cherepanov P**, Sun ZY, Rahman S, Maertens G, Wagner G, Engelman A. Solution structure of the HIV-1 integrase-binding domain in LEDGF/p75. *Nat Struct Mol Biol* 2005; **12**: 526-532 [PMID: 15895093 DOI: 10.1038/nsmb937]

117 **Engelman A**, Kessl JJ, Kvaratskhelia M. Allosteric inhibition of HIV-1 integrase activity. *Curr Opin Chem Biol* 2013; **17**: 339-345 [PMID: 23647983 DOI: 10.1016/j.cbpa.2013.04.010]

118 **Wang H**, Shun MC, Li X, Di Nunzio F, Hare S, Cherepanov P, Engelman A. Efficient Transduction of LEDGF/p75 Mutant Cells by Gain-of-Function HIV-1 Integrase Mutant Viruses. *Mol Ther Methods Clin Dev* 2014; **1** [PMID: 25383358 DOI: 10.1038/mtm.2013.2]

119 **Espeseth AS**, Felock P, Wolfe A, Witmer M, Grobler J, Anthony N, Egbertson M, Melamed JY, Young S, Hamill T, Cole JL, Hazuda DJ. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. *Proc Natl Acad Sci USA* 2000; **97**: 11244-11249 [PMID: 11016953 DOI: 10.1073/pnas.200139397]

120 **Beck-Engeser GB**, Eilat D, Harrer T, Jäck HM, Wabl M. Early onset of autoimmune disease by the retroviral integrase inhibitor raltegravir. *Proc Natl Acad Sci USA* 2009; **106**: 20865-20870 [PMID: 19923437 DOI: 10.1073/pnas.0908074106]

121 **Valkov E**, Gupta SS, Hare S, Helander A, Roversi P, McClure M, Cherepanov P. Functional and structural characterization of the integrase from the prototype foamy virus. *Nucleic Acids Res* 2009; **37**: 243-255 [PMID: 19036793 DOI: 10.1093/nar/gkn938]

122 **Koh Y**, Matreyek KA, Engelman A. Differential sensitivities of retroviruses to integrase strand transfer inhibitors. *J Virol* 2011; **85**: 3677-3682 [PMID: 21270168 DOI: 10.1128/JVI.02541-10]

123 **Pandey KK**, Bera S, Grandgenett DP. The HIV-1 integrase monomer induces a specific interaction with LTR DNA for concerted integration. *Biochemistry* 2011; **50**: 9788-9796 [PMID: 21992419 DOI: 10.1021/bi201247f]

124 **Li M**, Jurado KA, Lin S, Engelman A, Craigie R. Engineered hyperactive integrase for concerted HIV-1 DNA integration. *PLoS One* 2014; **9**: e105078 [PMID: 25119883 DOI: 10.1371/journal.pone.0105078]

125 **Zhao XZ**, Smith SJ, Maskell DP, Metifiot M, Pye VE, Fesen K, Marchand C, Pommier Y, Cherepanov P, Hughes SH, Burke TR. HIV-1 Integrase Strand Transfer Inhibitors with Reduced Susceptibility to Drug Resistant Mutant Integrases. *ACS Chem Biol* 2016; **11**: 1074-1081 [PMID: 26808478 DOI: 10.1021/acschembio.5b00948]

126 **Raheem IT**, Walji AM, Klein D, Sanders JM, Powell DA, Abeywickrema P, Barbe G, Bennet A, Childers K, Christensen M, Clas SD, Dubost D, Embrey M, Grobler J, Hafey MJ, Hartingh TJ, Hazuda DJ, Kuethe JT, McCabe Dunn J, Miller MD, Moore KP, Nolting A, Pajkovic N, Patel S, Peng Z, Rada V, Rearden P, Schreier JD, Sisko J, Steele TG, Truchon JF, Wai J, Xu M, Coleman PJ. Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors. *J Med Chem* 2015; **58**: 8154-8165 [PMID: 26397965 DOI: 10.1021/acs.jmedchem.5b01037]

127 **Métifiot M**, Maddali K, Johnson BC, Hare S, Smith SJ, Zhao XZ, Marchand C, Burke TR, Hughes SH, Cherepanov P, Pommier Y. Activities, crystal structures, and molecular dynamics of dihydro-1H-isoindole derivatives, inhibitors of HIV-1 integrase. *ACS Chem Biol* 2013; **8**: 209-217 [PMID: 23075516 DOI: 10.1021/cb300471n]

128 **Hare S**, Smith SJ, Métifiot M, Jaxa-Chamiec A, Pommier Y, Hughes SH, Cherepanov P. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). *Mol Pharmacol* 2011; **80**: 565-572 [PMID: 21719464 DOI: 10.1124/mol.111.073189]

129 **Hare S**, Vos AM, Clayton RF, Thuring JW, Cummings MD, Cherepanov P. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. *Proc Natl Acad Sci USA* 2010; **107**: 20057-20062 [PMID: 21030679 DOI: 10.1073/pnas.1010246107]

130 **Maskell DP**, Renault L, Serrao E, Lesbats P, Matadeen R, Hare S, Lindemann D, Engelman AN, Costa A, Cherepanov P. Structural basis for retroviral integration into nucleosomes. *Nature* 2015; **523**: 366-369 [PMID: 26061770 DOI: 10.1038/nature14495]

131 **Li M**, Lin S, Craigie R. Outer domains of integrase within retroviral intasomes are dispensible for catalysis of DNA integration. *Protein Sci* 2016; **25**: 472-478 [PMID: 26537415 DOI: 10.1002/pro.2837]

132 **Mazumder A**, Engelman A, Craigie R, Fesen M, Pommier Y. Intermolecular disintegration and intramolecular strand transfer activities of wild-type and mutant HIV-1 integrase. *Nucleic Acids Res* 1994; **22**: 1037-1043 [PMID: 8152908 DOI: 10.1093/nar/22.6.1037]

133 **Krishnan L**, Li X, Naraharisetty HL, Hare S, Cherepanov P, Engelman A. Structure-based modeling of the functional HIV-1 intasome and its inhibition. *Proc Natl Acad Sci USA* 2010; **107**: 15910-15915 [PMID: 20733078 DOI: 10.1073/pnas.1002346107]

134 **Serrao E**, Engelman AN. Sites of retroviral DNA integration: From basic research to clinical applications. *Crit Rev Biochem Mol Biol* 2016; **51**: 26-42 [PMID: 26508664 DOI: 10.3109/10409238.2015.1102859]

135 **Wang GP**, Ciuffi A, Leipzig J, Berry CC, Bushman FD. HIV integration site selection: analysis by massively parallel pyrosequencing reveals association with epigenetic modifications. *Genome Res* 2007; **17**: 1186-1194 [PMID: 17545577 DOI: 10.1101/gr.6286907]

136 **Schröder AR**, Shinn P, Chen H, Berry C, Ecker JR, Bushman F. HIV-1 integration in the human genome favors active genes and local hotspots. *Cell* 2002; **110**: 521-529 [PMID: 12202041 DOI: 10.1016/S0092-8674(02)00864-4]

137 **Singh PK**, Plumb MR, Ferris AL, Iben JR, Wu X, Fadel HJ, Luke BT, Esnault C, Poeschla EM, Hughes SH, Kvaratskhelia M, Levin HL. LEDGF/p75 interacts with mRNA splicing factors and targets HIV-1 integration to highly spliced genes. *Genes Dev* 2015; **29**: 2287-2297 [PMID: 26545813 DOI: 10.1101/gad.267609.115]

138 **Mitchell RS**, Beitzel BF, Schroder AR, Shinn P, Chen H, Berry CC, Ecker JR, Bushman FD. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. *PLoS Biol* 2004; **2**: E234 [PMID: 15314653 DOI: 10.1371/journal.pbio.0020234]

139 **Sowd GA**, Serrao E, Wang H, Wang W, Fadel HJ, Poeschla EM, Engelman AN. A critical role for alternative polyadenylation factor CPSF6 in targeting HIV-1 integration to transcriptionally active chromatin. *Proc Natl Acad Sci USA* 2016; **113**: E1054-E1063 [PMID: 26858452 DOI: 10.1073/pnas.1524213113]

140 **Trobridge GD**, Miller DG, Jacobs MA, Allen JM, Kiem HP, Kaul R, Russell DW. Foamy virus vector integration sites in normal human cells. *Proc Natl Acad Sci USA* 2006; **103**: 1498-1503 [PMID: 16428288 DOI: 10.1073/pnas.0510046103]

141 **Nowrouzi A**, Dittrich M, Klanke C, Heinkelein M, Rammling M, Dandekar T, von Kalle C, Rethwilm A. Genome-wide mapping of foamy virus vector integrations into a human cell line. *J Gen Virol* 2006; **87**: 1339-1347 [PMID: 16603537 DOI: 10.1099/vir.0.81554-0]

142 **Faschinger A**, Rouault F, Sollner J, Lukas A, Salmons B, Günzburg WH, Indik S. Mouse mammary tumor virus integration site selection in human and mouse genomes. *J Virol* 2008; **82**: 1360-1367 [PMID: 18032509 DOI: 10.1128/JVI.02098-07]

143 **Narezkina A**, Taganov KD, Litwin S, Stoyanova R, Hayashi J, Seeger C, Skalka AM, Katz RA. Genome-wide analyses of avian sarcoma virus integration sites. *J Virol* 2004; **78**: 11656-11663 [PMID: 15479807 DOI: 10.1128/JVI.78.21.11656-11663.2004]

144 **Pryciak PM**, Varmus HE. Nucleosomes, DNA-binding proteins, and DNA sequence modulate retroviral integration target site selection. *Cell* 1992; **69**: 769-780 [PMID: 1317268 DOI: 10.1016/0092-8674(92)90289-O]

145 **Pryciak PM**, Sil A, Varmus HE. Retroviral integration into minichromosomes in vitro. *EMBO J* 1992; **11**: 291-303 [PMID: 1310932]

146 **Pruss D**, Bushman FD, Wolffe AP. Human immunodeficiency virus integrase directs integration to sites of severe DNA distortion within the nucleosome core. *Proc Natl Acad Sci USA* 1994; **91**: 5913-5917 [PMID: 8016088 DOI: 10.1073/pnas.91.13.5913]

147 **Pruss D**, Reeves R, Bushman FD, Wolffe AP. The influence of DNA and nucleosome structure on integration events directed by HIV integrase. *J Biol Chem* 1994; **269**: 25031-25041 [PMID: 7929189]

148 **Roth SL**, Malani N, Bushman FD. Gammaretroviral integration into nucleosomal target DNA in vivo. *J Virol* 2011; **85**: 7393-7401 [PMID: 21561906 DOI: 10.1128/JVI00635-11]

149 **Serrao E**, Ballandras-Colas A, Cherepanov P, Maertens GN, Engelman AN. Key determinants of target DNA recognition by retroviral intasomes. *Retrovirology* 2015; **12**: 39 [PMID: 25924943 DOI: 10.1186/s12977-015-0167-3]

150 **Müller HP**, Varmus HE. DNA bending creates favored sites for retroviral integration: an explanation for preferred insertion sites in nucleosomes. *EMBO J* 1994; **13**: 4704-4714 [PMID: 7925312]

151 **Wu X**, Li Y, Crise B, Burgess SM, Munroe DJ. Weak palindromic consensus sequences are a common feature found at the integration target sites of many retroviruses. *J Virol* 2005; **79**: 5211-5214 [PMID: 15795304 DOI: 10.1128/JVI.79.8.5211-5214.2005]

152 **Serrao E**, Krishnan L, Shun MC, Li X, Cherepanov P, Engelman A, Maertens GN. Integrase residues that determine nucleotide preferences at sites of HIV-1 integration: implications for the mechanism of target DNA binding. *Nucleic Acids Res* 2014; **42**: 5164-5176 [PMID: 24520116 DOI: 10.1093/nar/gku136]

153 **Taganov KD**, Cuesta I, Daniel R, Cirillo LA, Katz RA, Zaret KS, Skalka AM. Integrase-specific enhancement and suppression of retroviral DNA integration by compacted chromatin structure in vitro. *J Virol* 2004; **78**: 5848-5855 [PMID: 15140982 DOI: 10.1128/JVI.78.11.5848-5855.2004]

154 **Benleulmi MS**, Matysiak J, Henriquez DR, Vaillant C, Lesbats P, Calmels C, Naughtin M, Leon O, Skalka AM, Ruff M, Lavigne M, Andreola ML, Parissi V. Intasome architecture and chromatin density modulate retroviral integration into nucleosome. *Retrovirology* 2015; **12**: 13 [PMID: 25807893 DOI: 10.1186/s12977-015-0145-9]

155 **Naughtin M**, Haftek-Terreau Z, Xavier J, Meyer S, Silvain M, Jaszczyszyn Y, Levy N, Miele V, Benleulmi MS, Ruff M, Parissi V, Vaillant C, Lavigne M. DNA Physical Properties and Nucleosome Positions Are Major Determinants of HIV-1 Integrase Selectivity. *PLoS One* 2015; **10**: e0129427 [PMID: 26075397 DOI: 10.1371/journal.pone.0129427]

156 **Pasi M**, Mornico D, Volant S, Juchet A, Batisse J, Bouchier C, Parissi V, Ruff M, Lavery R, Lavigne M. DNA minicircles clarify the specific role of DNA structure on retroviral integration. *Nucleic Acids Res* 2016; **44**: 7830-7847 [PMID: 27439712 DOI: 10.1093/nar/gkw651]

**P-Reviewer:** Arriagada GL, Kodama EN, Pandey KK **S-Editor:** Ji FF **L-Editor: E-Editor:**




Figure 1 Integrase catalytic functions and intasome complexes. A multimer of integrase (IN) (depicted simply by blue oval) engages the end regions of the linear vDNA molecule (yellow), forming the stable synaptic complex (SSC). During 3’-processing, IN hydrolyzes the vDNA ends adjacent to invariant CA dinucleotides, revealing a set of reactive 3’-hydroxyl groups in the confines of the cleaved donor complex (CDC). After nuclear localization, the target capture complex (TCC) is formed upon tDNA (black) capture. Strand transfer, whereby IN employs the 3’ hydroxyl groups as nucleophiles to attack the tDNA, marks the transition to the strand transfer complex (STC).







Figure 2 Integrase domain organization and representative secondary structures. Starting and ending residues for integrase (IN) domains are indicated above the boxes, and interdomain linker lengths as well as C-terminal tail lengths are indicated below the lines. Crystal structures of N-terminal domains (NTDs), catalytic core domains (CCDs), and C-terminal domains (CTDs) are provided underneath the corresponding schematic IN representation. Crystal structures in the absence of DNA are not available for the PFV NTD extension domain (NED), NTD, or CTD, as well as for the RSV NTD. PDB accession codes: HIV-1 (NTD, 1K6Y; CCD, 1BIU; CTD, 1EX4), PFV (CCD, 3DLR), RSV (CCD, 1C0M; CTD, 1C0M) and MMTV (NTD, 5CZ2; CCD, 5CZ1; CTD, 5D7U). HIV: Human immunodeficiency virus; PFV: Prototype foamy virus; RSV: Rous sarcoma virus; MMTV: Mouse mammary tumor virus.

****

**Figure 3 Comparison of prototype foamy virus, Rous sarcoma virus and β-retrovirus mouse mammary tumor virus intasomes.** A: The PFV intasome comprises two catalytic inner subunits (green and pink) and two outer supportive INs (cyan and light grey). Only the CCDs of the outer subunits are discernable in crystallographic electron density maps. RSV and MMTV share the PFV intasome core architecture and employ two additional flanking IN dimers (orange-purple and yellow-dark pink) to complete the intasome structures; B: Three-dimensional alignment of RSV (grey, PDB accession code 5EJK), PFV (yellow, PDB code 3L2Q), and MMTV (red, PDB code 3JCA) intasome structures was performed using Chimera. For the MMTV intasome, flanking dimers were unambiguously positioned into the intasome core of the cryo-EM map via rigid-body docking. The alignment reveals a high degree of flexibility (approximately 30-40 Å) for the flanking RSV and MMTV dimers relative to the common intasome core structures (arrows). PFV: Prototype foamy virus; RSV: Rous sarcoma virus; MMTV: Mouse mammary tumor virus.



**Figure 4 Integrase domain organizations within the prototype foamy virus, Rous sarcoma virus and β-retrovirus mouse mammary tumor virus intasome structures.** Separate integrase (IN) domains are labeled, with IN monomer coloring code retained from Figure 3. The green IN1 and pink IN3 monomers donate their active sites for catalysis of 3’ processing and strand transfer across the structures. Circled areas represent similarly positioned CTDs. While these emanate from inner IN1 and IN3 monomers in the PFV structure, they originate from flanking MMTV and RSV IN monomers IN6 and IN8. PDB accession codes same as in Figure 3. PFV: Prototype foamy virus; RSV: Rous sarcoma virus; MMTV: Mouse mammary tumor virus.



**Figure 5 Superposition of prototype foamy virus strand transfer complex, Rous sarcoma virus strand transfer complex, and mouse mammary tumor virus cleaved donor complex structures with respect to vDNA and tDNA. For simplicity, integrase content is either partially transparent or omitted.** Color-coding is as following: PFV DNA: Black; RSV DNA: Grey; MMTV DNA: Purple. 90° rotations show different angles of the intasomes. PDB accession codes: PFV STC: 3OS0, RSV STC: 5EJK, MMTV CDC: 3JCA. PFV: Prototype foamy virus; RSV: Rous sarcoma virus; MMTV: Mouse mammary tumor virus; STC: Strand transfer complex; CDC: Cleaved donor complex.